Seven Active Myasthenia Gravis Clinical Trials Currently Recruiting

It is essential for clinicians to remain informed about emerging clinical trial opportunities and resulting data that may inform therapeutic strategies, affect clinical guidelines, expand treatment options, and ultimately improve patient quality of life.

Today, we have a rundown of seven Phase 3 and 4 clinical trials for ocular and generalized myasthenia gravis. All trials featured today are currently recruiting in the United States as of June 16, 2026. Trials are arranged in order of their start date.

Quick View Table of Active Myasthenia Gravis Clinical Trials

Featured Phase 3 Clinical Trials

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis (MyVision)

• Sponsor: UCB Biopharma SRL
• Goal: The purpose of the study is to demonstrate the efficacy, safety and tolerability of rozanolixizumab compared with placebo in the treatment of adult study participants with Ocular Myasthenia Gravis.
• Interventions: Rozanolixizumab, placebo
• Primary Outcome Measure: Change from baseline at day 43 in (myasthenia gravis impairment index) MGII ocular score (patient-reported outcome (PRO) part)
• Time Frame: At day 43.
• Study Details
• Source

A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab (OCTAGON)

• Sponsor: Alexion Pharmaceuticals
• Goal: This is a prospective, multicenter single arm study designed to evaluate the effectiveness and safety of a predefined oral corticosteroids (OCS) tapering schedule to reduce OCS use in adult participants with acetylcholine receptor positive (AChR+) generalized myasthenia gravis (gMG) being treated with intravenous ravulizumab.
• Interventions: Oral corticosteroid tapering schedule, ravulizumab, prednisone/prednisolone
• Primary Outcome Measure: Proportion of adult participants with gMG who either: Discontinue oral corticosteroids (OCS) or reduce their daily OCS dosage ≤ 5 mg/day and maintain this status for ≥ four weeks without clinical deterioration of gMG.
• Time Frame: Up to approximately 32 weeks.
• Study Details
• Source

Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis (EPIC)

• Sponsor: Janssen Research & Development
• Goal: The purpose of this study is to assess how well nipocalimab works when compared to efgartigimod in participants with generalized myasthenia gravis (a condition in which body's immune system mistakenly attacks and damages the connection between nerves and muscles causing muscle weakness).
• Interventions: Nipocalimab, efgartigimod
• Primary Outcome Measure: Arms one and two: Averaged mean percent change from baseline in total immunoglobulin G (IgG) levels over weeks eight, 10 and 12.
• Time Frame: Baseline, weeks eight, 10, and 12.
• Study Details
• Source

Zilucoplan for Severe gMG Exacerbations

• Sponsor: Miriam Freimer
• Goal: This is an open-label, multicenter, interventional phase 3b study in participants with AChR+ gMG and severe exacerbation that require hospitalization. Patients will receive subcutaneous zilucoplan injections daily for 12 weeks. Participation in the study will last for approximately 18 weeks.
• Intervention: Zilucoplan
• Primary Outcome Measure: Change from baseline to week two in the myasthenia gravis – activities of daily living (MG-ADL) score.
• Time Frame: From baseline to week 2.
• Study Details
• Source

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

• Sponsor: Immunovant Sciences
• Goal: The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.
• Interventions: IMVT-1402, placebo
• Primary Outcome Measure: Change from Baseline in MG-ADL score for antibody-positive participants.
• Time Frame: Baseline to week 12.
• Study Details
• Source

A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG) (ADAPT-EARLY)

• Sponsor: Argenx
• Goal: The main purpose of this study is to measure how well adults with new-onset gMG (which means they've had generalized disease signs and/or symptoms for less than 1 year) respond to treatment with efgartigimod PH20 SC. The study consists of a treatment period of 51 weeks. The study duration for each participant will be approximately 58 weeks.
• Intervention: Efgartigimod PH20 SC
• Primary Outcome Measure: Proportion of participants who achieve MSE of MG at any time within the first 16 weeks of treatment with efgartigimod PH20 SC.
• Time Frame: Up to 16 weeks.
• Study Details
• Source

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis (RELIEVE)

• Sponsor: Novartis Pharmaceuticals
• Goal: A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment.
• Interventions: Remibrutinib (blinded), remibrutinib (open label), placebo
• Primary Outcome Measure: Change from baseline to Month 6 in Myasthenia Gravis Activity of Daily Living (MG-ADL) total score.
• Time Frame: Baseline to month six.
• Study Details
• Source

Related Clinical Guidance:

• Management of Myasthenia Gravis
  • Consensus and Physician Experts
  • November 2020

• Thymectomy for Autoimmune Myasthenia Gravis
  • American Academy of Neurology
  • March 2020

Check out our other neurology-focused insights and sign up for alerts and stay informed on the latest published guidelines.